| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4250832 | Seminars in Nuclear Medicine | 2016 | 4 Pages |
Abstract
Chemotherapy represents the cornerstone of treatment for patients with small cell lung cancer (SCLC); however, standard therapy has reached a plateau in improving patient survival with overall disappointing results. The demonstration that SCLC expresses neuroendocrine markers, such as somatostatin (SST) receptors, has led to use SST analogs or radiolabeled SST analogs in the treatment of SCLC patients. In the current review, we would focus on the possible role of SST analogs in SCLC.
Related Topics
Health Sciences
Medicine and Dentistry
Radiology and Imaging
Authors
Alfredo Tartarone, Rosa Lerose, Michele Aieta,